Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review.
By K. Boonstra, U. Beuers, C. Ponsioen. Journal of Hepatology, 2012
607 citations recorded by the source corpus.
OBJECTIVE Studies on the epidemiology of primary sclerosing cholangitis (PSC) and primary biliary cirrhosis (PBC) show variable outcome. We aimed at systematically reviewing the incidence and prevalence rates, as well as geographical distribution and temporal trends of PSC and PBC. DATA SOURCES A systematic search of literature was performed in Medline and EMBASE (search last conducted January 10th, 2011). STUDY SELECTION Population-based epidemiological studies reporting incidence and/or prevalence rates for PSC or PBC in a defined geographical area of at least 100,000 adult inhabitants were considered relevant. DATA EXTRACTION Study area, study period, number of patients, number of inhabitants, incidence per 100,000 inhabitants per year, prevalence per 100,000 inhabitants, method of case-finding, method of case-ascertainment, male/female ratio and in case of PSC, occurrence of inflammatory bowel diseases (IBD) were extracted from retrieved articles. RESULTS The literature search yielded 2286 abstracts of which 31 articles fulfilled all inclusion criteria. Studies varied in size from 10 to 770 patients in catchment areas from 100,312 to 19,230,000 inhabitants. The incidence and prevalence rates for PSC range from 0 to 1.3 per 100,000 inhabitants/year and 0-16.2 per 100,000 inhabitants, respectively. PBC incidence rates range from 0.33 to 5.8 per 100,000 inhabitants/year and prevalence rates range from 1.91 to 40.2 per 100,000 inhabitants; prevalence rates are increasing in time. CONCLUSIONS Incidence and prevalence rates of both PSC and PBC vary widely and seem to be increasing. True population-based studies are scarce and therefore large population-based studies combining meticulous case-finding and case-ascertainment strategies are necessary.
Subfields: Epidemiology, Hepatology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/bd30558a5105a3732ab0c260655ced780c7d78e5
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- K. Lindor
- C. Bowlus
- K. Boonstra
- R. Weersma
- Joost P. H. Drenth
- J. Boyer
- K. J. Erpecum
- M. Mayo
Citations in the corpus
- Population‐based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis (2013, result): “We report markedly lower incidence and prevalence rates of 0.5 per 100,000 and 6.0 per 100,000 inhabitants, respectively, compared to previous studies.17-20 Prevalence is rising with stable mortality over time (data not shown), which is in concordance with a recent systematic review and perhaps expl”
- Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2018, background): “(35, 36) However, the overall prevalence of the disease is increasing.(37)”